{"id":819600,"date":"2026-06-16T18:05:03","date_gmt":"2026-06-16T18:05:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=819600"},"modified":"2026-06-16T18:05:03","modified_gmt":"2026-06-16T18:05:03","slug":"charcot-marie-tooth-pipeline-shows-strong-momentum-as-13-pharma-companies-in-the-race-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/charcot-marie-tooth-pipeline-shows-strong-momentum-as-13-pharma-companies-in-the-race-delveinsight_819600.html","title":{"rendered":"Charcot Marie Tooth Pipeline Shows Strong Momentum as 13+ Pharma Companies in the Race | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781607690.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Charcot Marie Tooth Pipeline Shows Strong Momentum as 13+ Pharma Companies in the Race | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/06\/1781607690.jpg\" alt=\"Charcot Marie Tooth Pipeline Shows Strong Momentum as 13+ Pharma Companies in the Race | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>Charcot Marie Tooth Disease Pipeline Insight, 2026<\/strong>&rdquo; report provides comprehensive insights about <strong>13+ companies<\/strong> and <strong>15+ pipeline drugs<\/strong> in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Charcot Marie Tooth therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Curious about the latest updates in the Charcot Marie Tooth Pipeline? @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Charcot Marie Tooth Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><em><strong>On May 29, 2026, Novartis Pharmaceuticals<\/strong><\/em> conducted a study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants. The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS). The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.<\/li>\n<li><em><strong>On May 26, 2026- ENCell<\/strong> <\/em>initiated a phase 1b study was designed using the traditional 3+3 dose escalation method to confirm the maximum tolerated dose (MTD) and determine the recommended phase 2 dose (RP2D). This clinical trial consists of two stages (Phase 1b and Phase 2a). Phase 1b is designed with a 3+3 dose escalation design to evaluate the safety, including tolerability, of EN001 and explore efficacy. Phase 2a will evaluate the efficacy and safety of EN001 in comparison with placebo.<\/li>\n<li>DelveInsight&rsquo;s Charcot Marie Tooth Pipeline report depicts a robust space with 13+ active players working to develop 15+ pipeline therapies for Charcot Marie Tooth treatment.<\/li>\n<li>The leading Charcot Marie Tooth Companies include <strong><em>Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals,<\/em><\/strong> and others.<\/li>\n<li>Promising Charcot Marie Tooth Therapies such as <strong><em>PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD&reg;)<\/em><\/strong> and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Want to know which companies are leading innovation in Charcot Marie Tooth? Dive into the full pipeline insights @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Charcot Marie Tooth Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Charcot Marie Tooth Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Charcot-Marie-Tooth disease (CMT) is a group of inherited neurological disorders that affect the peripheral nerves, which are responsible for movement and sensation in the limbs. Named after the three physicians who first described it in 1886, CMT is also known as hereditary motor and sensory neuropathy (HMSN). It is one of the most common inherited neurological disorders, affecting about 1 in 2,500 people. CMT is characterized by progressive muscle weakness and atrophy, primarily in the legs and feet, and, in later stages, in the hands and arms.<\/p>\n<p style=\"text-align: justify;\"><strong>Charcot Marie Tooth Disease Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Ignaseclant: NMD PHARMA<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Ignaseclant (NMD670) is an investigational, first-in-class oral small molecule that selectively inhibits the skeletal muscle chloride channel ClC-1 chloride channel. By regulating this channel, it increases muscle excitability and enhances neuromuscular signal transmission. The therapy is being developed to improve muscle function and alleviate fatigue in patients with Charcot-Marie-Tooth disease. It is currently undergoing Phase II clinical evaluation for the treatment of Charcot-Marie-Tooth disease.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>EN001: ENCell<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">EN001 is an investigational therapeutic being developed for the treatment of Charcot-Marie-Tooth disease, a genetic disorder characterized by progressive muscle weakness and sensory loss. The drug is designed to enhance neuromuscular function by targeting pathways involved in muscle strength and nerve signaling. By improving muscle performance and reducing fatigue, EN001 aims to address key functional impairments associated with the disease. The drug has recently completed Phase I of clinical trials.<\/p>\n<p style=\"text-align: justify;\"><strong>If you&rsquo;re tracking ongoing Charcot Marie Tooth Clinical trials, this press release is a must-read @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Charcot Marie Tooth Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Charcot Marie Tooth Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine Therapeutics, Novartis Pharmaceuticals,<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>The Charcot Marie Tooth Pipeline report provides insights into:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Charcot Marie Tooth with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Charcot Marie Tooth Treatment.<\/li>\n<li>Charcot Marie Tooth Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Charcot Marie Tooth Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Charcot Marie Tooth market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Charcot Marie Tooth Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Parenteral<\/li>\n<li>Topical<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Charcot Marie Tooth Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Small molecule<\/li>\n<li>Monoclonal antibody<\/li>\n<li>Peptide<\/li>\n<li>Polymer<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>From emerging drug candidates to competitive intelligence, the Charcot Marie Tooth Pipeline Report covers it all @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Charcot Marie Tooth Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Charcot Marie Tooth Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Charcot Marie Tooth Companies-<strong><em> Pharnext SA, InFlectis BioScience, ENCell, HELIXMITH, Chong Kun Dang Pharmaceuticals, Addex Therapeutics, Augustine therapeutics, Novartis Pharmaceuticals,<\/em><\/strong> and others.<\/li>\n<li>Charcot Marie Tooth Therapies- <strong><em>PXT3003, NMD670, MD1003, Engensis (VM202), Remibrutinib, Teriflunomide, Cladribine (MAVENCLAD&reg;)<\/em><\/strong> and others.<\/li>\n<li>Charcot Marie Tooth Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Charcot Marie Tooth Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover what&rsquo;s next for the Charcot Marie Tooth Treatment landscape in this detailed analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/charcot-marie-tooth-disease-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Charcot Marie Tooth Emerging Drugs and Major Players<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Charcot Marie Tooth Disease: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Charcot Marie Tooth Disease&ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>PXT3003: Pharnext SA<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Drug Name: Company Name<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>IFB-088: InFlectis BioScience<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Preclinical and Discovery Stage Products<\/li>\n<li>Drug Name: Company Name<\/li>\n<li><em>Drug profiles in the detailed report&hellip;..<\/em><\/li>\n<li>Inactive Products<\/li>\n<li>Charcot Marie Tooth Disease Key Companies<\/li>\n<li>Charcot Marie Tooth Disease Key Products<\/li>\n<li>Charcot Marie Tooth Disease- Unmet Needs<\/li>\n<li>Charcot Marie Tooth Disease- Market Drivers and Barriers<\/li>\n<li>Charcot Marie Tooth Disease- Future Perspectives and Conclusion<\/li>\n<li>Charcot Marie Tooth Disease Analyst Views<\/li>\n<li>Charcot Marie Tooth Disease Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=charcot-marie-tooth-pipeline-shows-strong-momentum-as-13-pharma-companies-in-the-race-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/charcot-marie-tooth-disease-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/charcot-marie-tooth-disease-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=charcot-marie-tooth-pipeline-shows-strong-momentum-as-13-pharma-companies-in-the-race-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;Charcot Marie Tooth Disease Pipeline Insight, 2026&rdquo; report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Charcot Marie Tooth Disease pipeline landscape. It covers the Charcot Marie Tooth pipeline drug profiles, including clinical and nonclinical stage &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/charcot-marie-tooth-pipeline-shows-strong-momentum-as-13-pharma-companies-in-the-race-delveinsight_819600.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-819600","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/819600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=819600"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/819600\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=819600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=819600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=819600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}